232 related articles for article (PubMed ID: 25246014)
1. Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus.
Lynch AM; Pathak N; Flatt YE; Gault VA; O'Harte FP; Irwin N; Flatt PR
Eur J Pharmacol; 2014 Nov; 743():69-78. PubMed ID: 25246014
[TBL] [Abstract][Full Text] [Related]
2. (D-Ser2)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions.
Kerr BD; Flatt PR; Gault VA
Biochem Pharmacol; 2010 Dec; 80(11):1727-35. PubMed ID: 20735990
[TBL] [Abstract][Full Text] [Related]
3. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.
Bhat VK; Kerr BD; Flatt PR; Gault VA
Biochem Pharmacol; 2013 Jun; 85(11):1655-62. PubMed ID: 23518155
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-acting GIP, xenin and oxyntomodulin peptide analogues on alpha-cell transdifferentiation in insulin-deficient diabetic Glu
Sarnobat D; Moffett RC; Gault VA; Tanday N; Reimann F; Gribble FM; Flatt PR; Irwin N
Peptides; 2020 Mar; 125():170205. PubMed ID: 31738969
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
6. Sustained treatment with a stable long-acting oxyntomodulin analogue improves metabolic control and islet morphology in an experimental model of type 1 diabetes.
Irwin N; Pathak V; Pathak NM; Gault VA; Flatt PR
Diabetes Obes Metab; 2015 Sep; 17(9):887-95. PubMed ID: 26095087
[TBL] [Abstract][Full Text] [Related]
7. N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.
Green BD; Mooney MH; Gault VA; Irwin N; Bailey CJ; Harriott P; Greer B; O'Harte FP; Flatt PR
J Endocrinol; 2004 Mar; 180(3):379-88. PubMed ID: 15012592
[TBL] [Abstract][Full Text] [Related]
8. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
Green BD; Gault VA; Mooney MH; Irwin N; Harriott P; Greer B; Bailey CJ; O'Harte FP; Flatt PR
Biol Chem; 2004 Feb; 385(2):169-77. PubMed ID: 15101559
[TBL] [Abstract][Full Text] [Related]
9. Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice.
O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR
Mol Cell Endocrinol; 2016 Aug; 431():133-44. PubMed ID: 27179756
[TBL] [Abstract][Full Text] [Related]
10. A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation.
Lynch AM; Pathak N; Pathak V; O'Harte FP; Flatt PR; Irwin N; Gault VA
Diabetologia; 2014 Sep; 57(9):1927-36. PubMed ID: 24962667
[TBL] [Abstract][Full Text] [Related]
11. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
Gault VA; Kerr BD; Harriott P; Flatt PR
Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of oxyntomodulin and GLP-1 on glucose metabolism.
Du X; Kosinski JR; Lao J; Shen X; Petrov A; Chicchi GG; Eiermann GJ; Pocai A
Am J Physiol Endocrinol Metab; 2012 Jul; 303(2):E265-71. PubMed ID: 22621866
[TBL] [Abstract][Full Text] [Related]
13. A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity.
Bianchi E; Carrington PE; Ingallinella P; Finotto M; Santoprete A; Petrov A; Eiermann G; Kosinski J; Marsh DJ; Pocai A; SinhaRoy R; Pessi A
Bioorg Med Chem; 2013 Nov; 21(22):7064-73. PubMed ID: 24094437
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 inhibits insulinotropic effects of oxyntomodulin and glucagon in cattle.
ThanThan S; Saito T; Yannaing S; Zhao H; Nakashima K; Kuwayama H
Domest Anim Endocrinol; 2012 Apr; 42(3):155-64. PubMed ID: 22154917
[TBL] [Abstract][Full Text] [Related]
15. Oxyntomodulin analog and exendin-4 derivative lower plasma glucose in cattle.
ThanThan S; Asada Y; Saito T; Ochiiwa K; Zhao H; Naing SW; Kuwayama H
Domest Anim Endocrinol; 2017 Apr; 59():30-36. PubMed ID: 27888738
[TBL] [Abstract][Full Text] [Related]
16. Apelin-13 analogues show potent in vitro and in vivo insulinotropic and glucose lowering actions.
O'Harte FPM; Parthsarathy V; Hogg C; Flatt PR
Peptides; 2018 Feb; 100():219-228. PubMed ID: 29412822
[TBL] [Abstract][Full Text] [Related]
17. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
Bhat VK; Kerr BD; Vasu S; Flatt PR; Gault VA
Diabetologia; 2013 Jun; 56(6):1417-24. PubMed ID: 23503814
[TBL] [Abstract][Full Text] [Related]
18. S3-2, a novel long-lasting oxyntomodulin derivative, exerts improvement on diabesity and renal injury through activating GLP-1 and glucagon receptors.
Huang P; Meng L; Tan J; Gu X; Huang M; Huang F; Ma R; Wang J
Life Sci; 2021 Apr; 270():119136. PubMed ID: 33508289
[TBL] [Abstract][Full Text] [Related]
19. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.
Maida A; Lovshin JA; Baggio LL; Drucker DJ
Endocrinology; 2008 Nov; 149(11):5670-8. PubMed ID: 18669601
[TBL] [Abstract][Full Text] [Related]
20. DPP-IV-resistant, long-acting oxyntomodulin derivatives.
Santoprete A; Capitò E; Carrington PE; Pocai A; Finotto M; Langella A; Ingallinella P; Zytko K; Bufali S; Cianetti S; Veneziano M; Bonelli F; Zhu L; Monteagudo E; Marsh DJ; Sinharoy R; Bianchi E; Pessi A
J Pept Sci; 2011 Apr; 17(4):270-80. PubMed ID: 21294225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
